FIELD: biotechnology.
SUBSTANCE: protein antigen is described for the prevention and/or treatment of SARS-CoV-2 infection, characterized by the following: it contains a domain that binds to the angiotensin-converting enzyme 2 (ACE2) receptor contained in the SARS-CoV-2 S protein, where the amino acid sequence of the said domain is at least one of SEQ ID No. 3 or SEQ ID NO: 4. A polynucleotide encoding the specified agent, as well as the production of the specified agent, are presented.
EFFECT: invention expands the range of means for preventing and/or treating SARS-CoV-2 infection.
15 cl, 15 dwg, 8 ex
Title | Year | Author | Number |
---|---|---|---|
AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-COV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-COV-2 | 2020 |
|
RU2760301C1 |
VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY TO THE SARS-CoV-2 VIRUS AND/OR THE PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2021 |
|
RU2761879C1 |
VACCINE BASED ON AAV5 FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-CoV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2020 |
|
RU2783313C1 |
SINGLE-DOMAIN ANTIBODY AND ITS MODIFICATIONS THAT SPECIFICALLY BIND TO RBDS PROTEIN OF SARS-COV-2 VIRUS, AND METHOD FOR THEIR USE FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS- COV-2 VIRUS | 2021 |
|
RU2763001C1 |
ADVANCED CORONAVIRUS VACCINE | 2022 |
|
RU2816182C2 |
GENE CONSTRUCT FOR THE EXPRESSION OF RECOMBINANT PROTEINS BASED ON THE SEGMENT OF THE SARS-COV-2 S-PROTEIN, INCLUDING RBD AND SD1, FUSED WITH THE FC FRAGMENT OF IGG, A METHOD OF OBTAINING RECOMBINANT PROTEINS, ANTIGENS AND ANTIGENIC COMPOSITIONS FOR THE INDUCTION OF LONG-TERM ANTIBODY AND CELLULAR IMMUNITY AGAINST SARS-CO-2 | 2021 |
|
RU2802825C2 |
ISOLATED RECOMBINANT VIRUS BASED ON INFLUENZA VIRUS FOR INDUCING SPECIFIC IMMUNITY TO INFLUENZA VIRUS AND/OR PREVENTING DISEASES CAUSED BY INFLUENZA VIRUS | 2021 |
|
RU2813150C2 |
ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
HUMANIZED MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO RBD S OF THE PROTEIN OF THE SARS-COV-2 VIRUS, AGENT AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS-COV-2 VIRUS | 2021 |
|
RU2765731C1 |
MEANS AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY THE SARS-COV-2 VIRUS BASED ON A RECOMBINANT ANTIBODY AND A HUMANIZED MONOCLONAL ANTIBODY | 2021 |
|
RU2769223C1 |
Authors
Dates
2024-03-11—Published
2020-09-18—Filed